Bayer hits Mylan with Nexavar lawsuit
Germany-based healthcare company Bayer HealthCare has sued Mylan Pharmaceuticals over the alleged infringement of five of its patents.
In a complaint filed on Thursday, December 17, at the US District Court for the District of Delaware, Bayer claimed that Mylan’s attempt to market a generic version of Nexavar (sorafenib) infringes its intellectual property.
Nexavar is used to treat kidney cancer and hepatocellular carcinoma, a type of cancer that affects the liver.
Mylan informed Bayer of its Abbreviated New Drug Application (ANDA) to market the Nexavar generic on November 5, 2015.
Bayer said: “Mylan’s notice letters did not provide a valid basis for concluding that the manufactu re, use offer for sale, sale, marketing distribution, and/or importation of Mylan’s ANDA product would not infringe at least one valid and enforceable claim” of the asserted patents.
The German company is seeking a declaration that the patents are valid and that the court award an injunction preventing Mylan from releasing its proposed generic.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk